Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

This study has been terminated.
(The study was terminated for business planning purposes. Assessments of APOCIIIRx in this population will be explored in a larger efficacy study)
Sponsor:
Information provided by (Responsible Party):
Isis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01647308
First received: July 19, 2012
Last updated: July 11, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2014
  Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)